Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads CT scans to measure muscle and fat: will it beat the experts?

NCT ID NCT07600866

Diagnosis Sponsor: Nucleo Research, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new AI software called Soma that automatically measures muscle and fat from CT scans. Researchers will compare the software's measurements to those made by three expert radiologists using 200 CT scans from public databases. The goal is to see if the AI is accurate enough to help diagnose conditions like muscle loss (sarcopenia) and obesity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Soma Body-Composition Segmentation Software (diagnostic test)
What this could lead to
If successful, this software could help doctors quickly and accurately measure muscle and fat from CT scans, aiding in the diagnosis of conditions like sarcopenia and obesity.
What could go wrong
This is a small, early validation study using existing scans, not a real-world test. The software may not perform as well in different hospitals or on different types of patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects older than 16 years old whose de-identified abdominal CT imaging is available from one of six publicly accessible imaging datasets (autoPET, AMOS, MSD Pancreas, CT-ORG, ENHANCE.PET, RATIC). The 200-scan study cohort is selected by stratified sampling from a curated pool of 2,066 scans to ensure representation across BMI category, age band, sex, body region (abdomen-only vs. whole-body), and clinical context (oncologic vs. non-oncologic).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects above 16 years or older at the time the source imaging was acquired. * De-identified abdominal computed tomography (CT) scan available from one of the six predefined publicly available datasets (autoPET, AMOS, MSD Pancreas, CT-ORG, ENHANCE.PET, or RATIC). * Scan covers the third lumbar vertebra (L3) with a contiguous axial slice suitable for L3-level body-composition analysis. * Demographic metadata required for stratified sampling (age, sex; BMI where available; clinical context as encoded in source dataset) is present. Exclusion Criteria: * Subject under 16 years of age at the time the source imaging was acquired. * Scan does not include the L3 vertebra or has severe motion artifact, truncation, or metallic artifact precluding analysis at the L3 level. * Duplicate or near-duplicate scans of the same subject already included in the cohort. * Missing demographic metadata required for at least one stratification axis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Body composition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Body composition Obesity Sarcopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Nucleo Research, Inc.

    San Francisco, California, 94133, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.